U.S.-based Beckman Coulter Life Science has released three new DuraClone RE dry reagent kits meant for the quick and accurate detection of rare cell populations.
The DuraClone RE antibody panels provide tools to study low-frequency populations of either abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC) or abnormal B progenitor cells (RE ALB). The kits also are able to accommodate either large sample volumes or high cellular concentrations. Using dry, unitized antibody combinations helps preserve the strict assay conditions essential for reliable, reproducible rare event analysis.
The company said the products are ideal for clinical research studies of blood disorders.
“Research of rare abnormal cells associated with blood disorders is powerful, yet challenging to perform,” explained Mario Koksch, vice-president and general manager of Beckman Coulter’s cytometry business unit. “…we recognize that preserving strict assay conditions is integral to rare event analysis. This has led to the development of our next generation DuraClone RE kits, produced in collaboration with experts from leading clinical research laboratories.”
According to these research labs, streamlined workflow and standardization of results were essential to the experimental robustness of their longitudinal and multi-centric research into blood disorders, said Kosch.
The new kits will simplify rare event analysis said Prof. Karl-Anton Kreuzer, of the Center for Integrated Oncology (CIO), in Colonge. Kreuzer recently carried out a trial using the kits and commented.
“The inclusion of ROR-1 as a new discriminative marker has markedly facilitated the screening for low frequencies of abnormal B cells,” said Kreuzer.
DuraClone RE antibody panels are available in a convenient 25-test package containing three complete compensation kits specific for each panel. They feature additional antibody drop-in slots, making it possible to answer a customer’s specific questions.
Beckman Coulter is also developing other additions to the DuraClone line, including dry stimulation cocktails for functional assays.